CYP4F2 and lung cancer: Therefore, CYP4F2 can be used as a new target to improve the therapeutic efficacy of anti‐programmed death receptor‐1 (PD‐1) therapy, and the combination of CYP4F inhibitors and PD‐1 inhibitors will be a new combination drug strategy for lung cancer immunotherapy.293